<i>nab</i>-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study

201015 citationsJournal Article

Authors

M. Biakhov · Central Clinical Hospital No 2 named Semashko

G. Kononova

José Iglesias · Abraxis (United States)

Neil Desai · Abraxis (United States)

Paul Bhar · Abraxis (United States)

Anita N. Schmid · Abraxis (United States)

Sibylle Loibl · Weatherford College

Abstract

nab-Paclitaxel has an acceptable tolerability profile in patients with solid tumors and hepatic dysfunction. The safety and pharmacokinetic results support the same dose modification scheme recommended for cremophor-based paclitaxel.

Topics & Keywords

Cancer Treatment and Pharmacology Colorectal Cancer Treatments and Studies Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Expert Opinion on Drug Safety

Volume 9, Issue 4, pp. 515-523

DOI: 10.1517/14740338.2010.487063

Field-Weighted Citation Impact: 0.51